secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001193125-24-085437
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma to merge with Oruka; Oruka holders to own ~97.6% of combined company
--------------------------------------------------------------------------------

- Oruka stockholders to own ~97.62% of the combined company; ARCA stockholders ~2.38%.
- Combined company to be renamed Oruka Therapeutics, led by Oruka's CEO.
- PIPE financing of ~$275M from accredited investors to close immediately before the merger.
- Oruka holders (~90%) and ARCA holders (~28.5%) entered support agreements to vote in favor.
- Closing conditions include ARCA stockholder approval, Nasdaq listing, and HSR clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/0001193125-24-085437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-085437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer